tiprankstipranks
Balchem Corp. (BCPC)
NASDAQ:BCPC
US Market
Want to see BCPC full AI Analyst Report?

Balchem (BCPC) Earnings Dates, Call Summary & Reports

176 Followers

Earnings Data

Report Date
Jul 24, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
1.31
Last Year’s EPS
1.17
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:Apr 30, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented multiple record financial metrics (revenue, adjusted EBITDA, adjusted EPS, gross margin dollars) and showcased broad-based growth across all three segments, strong cash generation, improved margins, sustainability achievements, and promising branded-ingredient progress (notably Vidacholine). Headwinds include emerging petrochemical-driven inflation, higher operating expenses tied to growth investments, and geopolitical-related supply-chain/freight risk that could cause modest margin compression in the near term. Overall, the positive operational and financial momentum, coupled with manageable leverage and clear strategic initiatives, outweigh the noted risks.
Company Guidance
Balchem guided to continued quarterly year‑over‑year consolidated growth over the coming quarters while warning of modest margin compression from input‑cost inflation—especially in Animal Nutrition & Health—and saying it will use procurement, pricing actions and supply‑chain measures to mitigate pressures; management uses a ~23% effective tax planning rate (Q1 ETR 23.3%, Q2 expected higher, back half trending toward ~23%) and reiterated confidence in delivering continued top‑ and bottom‑line growth. As context, Q1 results were: revenue $271M (+8.1% YoY), gross margin $101M (37.3% of sales, +210 bps; gross margin dollars +14.6%), GAAP operating income $56M (+9%), adjusted operating income $61M (+9.5%), adjusted EBITDA $74M (+12.1%) with a 27.4% adjusted EBITDA margin, net income $40M (+8.7%), GAAP diluted EPS $1.25 (+10.6%), adjusted net earnings $43M (+7.4%) or $1.33 per diluted share, operating expenses $45M, cash from operations $40M, free cash flow $34M, cash on hand $73M, net debt $96M (net leverage 0.3), and net interest expense of ~$2M.
Record Consolidated Revenue and Sales Growth
Reported record Q1 consolidated net sales of $271.0M, up 8.1% year-over-year; ~2% of the sales growth was favorably impacted by foreign currency (stronger euro).
Record Profitability and EPS Expansion
Delivered record GAAP earnings from operations of $56.0M (up 9%), consolidated net income of $40.0M (up 8.7%), GAAP diluted EPS $1.25 (up 10.6%), and adjusted EPS $1.33 (up 9%).
Adjusted EBITDA and Margin Strength
Record adjusted EBITDA of $74.0M, a 12.1% increase year-over-year, with an adjusted EBITDA margin rate of 27.4%.
Gross Margin Expansion
Gross margin dollars of $101.0M, up 14.6%, and gross margin rate expanded to 37.3% of sales (up 210 basis points) driven by sales mix (higher-margin businesses growing faster), manufacturing efficiencies, and price/inflation management.
Segment-Level Growth Across All Businesses
Human Nutrition & Health sales $172M (up 8.3%) with segment OI $40M (up 5.4%); Animal Nutrition & Health sales $62M (up 8.6%) with segment OI $6M (up ~8.7%); Specialty Products sales $35M (up 4.4%) with segment OI $12M (up 24.5%). All three segments delivered year-over-year sales and earnings growth.
Cash Generation and Strong Balance Sheet Metrics
Operating cash flow of $40M, free cash flow of $34M, cash on hand of $73M, net debt $96M and net leverage of 0.3, and net interest expense down $1M to $2M.
Sustainability Milestone
Surpassed 2030 greenhouse gas target early: reduced scope 1 & 2 GHG emissions ~31% vs 2020 baseline (target was 25% by 2030); water withdrawal reduced ~16% vs 2020 baseline.
Continued Momentum in Branded Ingredients and Commercial Expansion
Branded ingredients (e.g., Vidacholine, K2 Vital, Opti MSM) account for ~40-50% of Human Nutrition & Health and are growing faster than other portfolio parts; Vidacholine received new peer-reviewed positive fMRI clinical data supporting cognitive benefits in postmenopausal women, supporting expansion into larger adult cognition markets.
Long Track Record of Margin Growth
Delivered the 27th consecutive quarter of year-over-year growth in adjusted EBITDA, demonstrating consistent operational performance across a volatile multi-year environment.

Balchem (BCPC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

BCPC Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 24, 2026
2026 (Q2)
1.30 / -
1.17
Apr 30, 2026
2026 (Q1)
1.25 / 1.25
1.1310.62% (+0.12)
Feb 20, 2026
2025 (Q4)
1.18 / 1.21
1.0317.48% (+0.18)
Oct 21, 2025
2025 (Q3)
1.16 / 1.24
1.0320.39% (+0.21)
Jul 31, 2025
2025 (Q2)
1.12 / 1.17
1.097.34% (+0.08)
Apr 24, 2025
2025 (Q1)
1.04 / 1.13
1.039.71% (+0.10)
Feb 21, 2025
2024 (Q4)
1.05 / 1.03
0.958.42% (+0.08)
Oct 25, 2024
2024 (Q3)
1.11 / 1.03
1.04-0.96% (-0.01)
Jul 26, 2024
2024 (Q2)
1.03 / 1.09
1.062.83% (+0.03)
May 03, 2024
2024 (Q1)
0.98 / 1.03
0.949.57% (+0.09)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

BCPC Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 30, 2026
$173.33$161.62-6.76%
Feb 20, 2026
$175.00$171.30-2.11%
Oct 21, 2025
$149.85$155.93+4.06%
Jul 31, 2025
$151.16$151.54+0.25%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Balchem Corp. (BCPC) report earnings?
Balchem Corp. (BCPC) is schdueled to report earning on Jul 24, 2026, Before Open (Confirmed).
    What is Balchem Corp. (BCPC) earnings time?
    Balchem Corp. (BCPC) earnings time is at Jul 24, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is BCPC EPS forecast?
          BCPC EPS forecast for the fiscal quarter 2026 (Q2) is 1.31.